- Home
- CLM vs ARVN Comparison
CLM vs ARVN Comparison
Compare CLM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- ARVN
- Stock Information
- Founded
- CLM 1987
- ARVN 2015
- Country
- CLM United States
- ARVN United States
- Employees
- CLM N/A
- ARVN N/A
- Industry
- CLM Finance/Investors Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CLM Finance
- ARVN Health Care
- Exchange
- CLM Nasdaq
- ARVN Nasdaq
- Market Cap
- CLM 2.1B
- ARVN 1.8B
- IPO Year
- CLM N/A
- ARVN 2018
- Fundamental
- Price
- CLM $8.43
- ARVN $18.48
- Analyst Decision
- CLM
- ARVN Strong Buy
- Analyst Count
- CLM 0
- ARVN 13
- Target Price
- CLM N/A
- ARVN $63.00
- AVG Volume (30 Days)
- CLM 1.4M
- ARVN 967.8K
- Earning Date
- CLM 01-01-0001
- ARVN 10-30-2024
- Dividend Yield
- CLM 18.74%
- ARVN N/A
- EPS Growth
- CLM N/A
- ARVN N/A
- EPS
- CLM N/A
- ARVN N/A
- Revenue
- CLM N/A
- ARVN $161,100,000.00
- Revenue This Year
- CLM N/A
- ARVN $237.44
- Revenue Next Year
- CLM N/A
- ARVN N/A
- P/E Ratio
- CLM N/A
- ARVN N/A
- Revenue Growth
- CLM N/A
- ARVN 1.07
- 52 Week Low
- CLM $6.25
- ARVN $17.37
- 52 Week High
- CLM $8.84
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- CLM 45.19
- ARVN 32.78
- Support Level
- CLM $8.16
- ARVN $17.37
- Resistance Level
- CLM $8.80
- ARVN $19.21
- Average True Range (ATR)
- CLM 0.25
- ARVN 1.64
- MACD
- CLM -0.09
- ARVN -0.59
- Stochastic Oscillator
- CLM 35.52
- ARVN 11.80
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.